Immunotherapy for the Treatment of Cancer

Using our proprietary platform technology, GT Biopharma is generating novel immuno-oncology biopharmaceutical drugs targeting cancers such as acute lymphocytic leukemia, non-Hodgkin's lymphoma, acute myeloid leukemia and multiple solid tumors.

View Product Pipeline


GT Biopharma, Inc. a targeted immunotherapies company.


Latest News

GT Biopharma Announces Dr. Greg Berk, M.D. Joins Board of Directors
Nov 19, 2020 • 7:30 EST | Read More

GT Biopharma Appoints Michael Handelman, CPA as Chief Financial Officer
Nov 18, 2020 • 7:30 EST | Read More


GT Biopharma, Inc. OTCQB: GTBP
Loading... Change
Loading... Volume
Loading... 52 Week Range